Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04027972 · ClinicalTrials.gov registry record · Early Phase 1
Pharmacokinetics of Neostigmine and Glycopyrrolate
A Early Phase 1 study, sponsored by James J. Peters Veterans Affairs Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 13
- Enrollment target
NCT04027972 is a Early Phase 1 study that has completed, run by James J. Peters Veterans Affairs Medical Center. The registered enrollment target is 13 participants.
The verdict
NCT04027972, a Early Phase 1 study, has completed, sponsored by James J. Peters Veterans Affairs Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
A group of 6 able-bodied healthy volunteers will receive Neostigmine (NEO) and Glycopyrrolate (GLY) intravenously and via 2 methods of Iontophoresis (ION): one-patch and two-patch administration, with subsequent blood draws over 1 hour in order to measure the pharmacokinetic behavior of the drugs in-vivo.
Interventions
- DRUG Combination of Neostigmine and Glycopyrrolate
- DEVICE I-Box by Dynatronics
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2020-03-09 |
| Est. Completion | 2022-12-20 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04027972
The ClinicalTrials.gov registry entry for NCT04027972 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is James J. Peters Veterans Affairs Medical Center, which has 39 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Combination of Neostigmine and Glycopyrrolate is the first listed.
NCT04027972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04027972 about?
NCT04027972 is a clinical study titled "Pharmacokinetics of Neostigmine and Glycopyrrolate". A group of 6 able-bodied healthy volunteers will receive Neostigmine (NEO) and Glycopyrrolate (GLY) intravenously and via 2 methods of Iontophoresis (ION): one-patch and two-patch administration, with subsequent blood draws over 1 hour in order to measure the pharmacokinetic behavior of the drugs in...
What is the current status of trial NCT04027972?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 13 participants. The study started on 2020-03-09. Estimated completion is 2022-12-20.
What interventions are being tested in trial NCT04027972?
The interventions under investigation include: Combination of Neostigmine and Glycopyrrolate (DRUG), I-Box by Dynatronics (DEVICE).
Who is sponsoring clinical trial NCT04027972?
This trial is sponsored by James J. Peters Veterans Affairs Medical Center, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.